Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares were down 3.3% during mid-day trading on Monday . The stock traded as low as $21.02 and last traded at $21.06. Approximately 171,310 shares were traded during trading, a decline of 85% from the average daily volume of 1,145,589 shares. The stock had previously closed at $21.78.
Analysts Set New Price Targets
A number of brokerages have commented on CAPR. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an "overweight" rating and a $35.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Oppenheimer restated an "outperform" rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Finally, Maxim Group upped their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $24.67.
Get Our Latest Stock Report on Capricor Therapeutics
Capricor Therapeutics Price Performance
The company's fifty day simple moving average is $10.76 and its 200 day simple moving average is $7.03.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. On average, sell-side analysts predict that Capricor Therapeutics Inc will post -1.17 earnings per share for the current fiscal year.
Insider Activity
In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the company's stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 12.00% of the stock is currently owned by company insiders.
Institutional Trading of Capricor Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after buying an additional 84,350 shares during the last quarter. Marshall Wace LLP bought a new stake in Capricor Therapeutics in the 2nd quarter worth about $426,000. Rhumbline Advisers bought a new stake in Capricor Therapeutics in the 2nd quarter worth about $147,000. Finally, BNP Paribas Financial Markets purchased a new position in Capricor Therapeutics in the 1st quarter worth about $40,000. 21.68% of the stock is owned by institutional investors.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
